Research Group for Clinical Bioinformatics, Institute of Electrical, Electronic and Bioengineering, University for Health Sciences, Medical Informatics and Technology (UMIT), A-6060 Hall in Tirol, Austria.
Bioinformatics. 2010 Jul 15;26(14):1745-51. doi: 10.1093/bioinformatics/btq254. Epub 2010 May 18.
The discovery of new and unexpected biomarkers in cardiovascular disease is a highly data-driven process that requires the complementary power of modern metabolite profiling technologies, bioinformatics and biostatistics. Clinical biomarkers of early myocardial injury are lacking. A prospective biomarker cohort study was carried out to identify, categorize and profile kinetic patterns of early metabolic biomarkers of planned myocardial infarction (PMI) and spontaneous (SMI) myocardial infarction. We applied a targeted mass spectrometry (MS)-based metabolite profiling platform to serial blood samples drawn from carefully phenotyped patients undergoing alcohol septal ablation for hypertrophic obstructive cardiomyopathy serving as a human model of PMI. Patients with SMI and patients undergoing catheterization without induction of myocardial infarction served as positive and negative controls to assess generalizability of markers identified in PMI.
To identify metabolites of high predictive value in tandem mass spectrometry data, we introduced a new feature selection method for the categorization of metabolic signatures into three classes of weak, moderate and strong predictors, which can be easily applied to both paired and unpaired samples. Our paradigm outperformed standard null-hypothesis significance testing and other popular methods for feature selection in terms of the area under the receiver operating curve and the product of sensitivity and specificity. Our results emphasize that this new method was able to identify, classify and validate alterations of levels in multiple metabolites participating in pathways associated with myocardial injury as early as 10 min after PMI.
The algorithm as well as supplementary material is available for download at: www.umit.at/page.cfm?vpath=departments/technik/iebe/tools/bi
心血管疾病中新的和意外的生物标志物的发现是一个高度数据驱动的过程,需要现代代谢物分析技术、生物信息学和生物统计学的互补力量。目前缺乏早期心肌损伤的临床生物标志物。进行了一项前瞻性生物标志物队列研究,以识别、分类和分析计划心肌梗死(PMI)和自发性(SMI)心肌梗死的早期代谢生物标志物的动力学模式。我们应用靶向质谱(MS)代谢物分析平台对接受酒精间隔消融术治疗肥厚型梗阻性心肌病的患者进行连续采血,这些患者是 PMI 的人类模型。将 SMI 患者和未进行心肌梗死诱导的导管插入术患者作为阳性和阴性对照,以评估在 PMI 中鉴定出的标志物的普遍性。
为了在串联质谱数据中识别具有高预测价值的代谢物,我们引入了一种新的特征选择方法,将代谢特征分类为弱、中、强预测器三个类别,该方法可轻松应用于配对和非配对样本。与标准零假设检验和其他流行的特征选择方法相比,我们的范例在接收器操作曲线下面积和敏感性与特异性的乘积方面表现出色。我们的结果强调,这种新方法能够识别、分类和验证参与与心肌损伤相关途径的多个代谢物水平的变化,最早在 PMI 后 10 分钟即可发生。
算法和补充材料可在以下网址下载:www.umit.at/page.cfm?vpath=departments/technik/iebe/tools/bi